Biogen's Anti-Tau Drug Diranersen Shows 38% Slowing of Alzheimer's Decline at Two Years in Open-Label Data
SentiSense · Published · Updated
Biogen said its tau-lowering drug diranersen (BIIB080), developed with Ionis, slowed clinical decline by 38% on the CDR-SB scale at week 96 in the 60 mg twice-yearly arm of its Phase 2 CELIA study, up from 26% at week 76. The two-year figures come from an open-label extension with 60 patients in that arm and were presented at the CTAD conference in Boston on November 17.
BIIB reported two-year data for diranersen, an experimental drug designed to reduce production of tau in the brain, developed with IONS. In the 60 mg twice-yearly arm of the Phase 2 CELIA study, patients with early Alzheimer's disease showed a 38% slowing of clinical decline on the CDR-SB scale at week 96, a 1.09-point difference, up from 26% at week 76. The data were presented on November 17 at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston.
Other measures moved the same way: slowing on ADAS-Cog13 widened to 54% from 42%, and on the modified iADRS to 46% from 30%. Biogen described the results as the first evidence that a tau-targeting treatment may slow cognitive decline in Alzheimer's disease.
The caveats are significant. The two-year figures come from an open-label extension rather than the randomized phase, with 60 patients in the 60 mg arm, and patients who had been on placebo had received no dose or one dose by week 96. The study also missed its primary dose-response endpoint at week 76 in May, because higher doses did not add benefit over the lowest dose. Biogen says the data support moving to Phase 3. The readout is a single program update and no share-price reaction was reported alongside it.
Separately, Biogen told the Jefferies Global Healthcare Conference that its turnaround is nearing growth, building on a third-quarter call where it said core pharmaceutical revenue expanded 18% and the Apellis acquisition added a $1 billion annual run-rate asset base. What to watch: Phase 3 design and timing for diranersen, and whether regulators and investors give weight to open-label extension data.
Related Stocks
Powered by SentiSense - Intelligent Market Analysis